ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,052.31
0.68%
Dow Jones
38,145.43
0.64%
US Dollar vs MXN
16.93847
-0.03%
Brent Oil
83.56
0.02%
Bitcoin
58,982.01
1.28%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. 4D Molecular Therapeutics Inc (FDMT)

  7. 4D Molecular Therapeutics Inc (FDMT) Noticias

FDMT 4D Molecular Therapeutics Inc

26.34
0.95 (3.74%)
Última actualización: 12:28:20
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
4D Molecular Therapeutics Inc FDMT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.95 3.74% 26.34 12:28:20
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
25.31 24.93 26.41 25.39
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/5/202407:00GLOBE4DMT Announces Presentations at ARVO 2024 Annual Meeting
28/3/202407:00GLOBE4DMT Announces Update on Regulatory Interactions and..
04/3/202407:00GLOBE4DMT to Participate in Upcoming Investor Conferences
29/2/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202416:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
29/2/202415:12EDGAR2Form 8-K - Current report
29/2/202415:05GLOBE4DMT Reports Full Year 2023 Financial Results and..
21/2/202416:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202419:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202407:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202420:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202419:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202407:00GLOBE4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2..
09/2/202415:56EDGAR2Form 8-K - Current report
08/2/202415:50EDGAR2Form 144 - Report of proposed sale of securities
08/2/202415:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/2/202415:22EDGAR2Form 144 - Report of proposed sale of securities
07/2/202419:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202418:42EDGAR2Form 3/A - Initial statement of beneficial ownership of..
06/2/202422:27GLOBE4D Molecular Therapeutics Announces Pricing of Upsized..
05/2/202416:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/2/202415:35EDGAR2Form S-3ASR - Automatic shelf registration statement of..
05/2/202415:05GLOBE4D Molecular Therapeutics Announces Proposed Public Offering..
03/2/202416:00GLOBE4DMT Presents Positive Interim Data from Randomized Phase 2..
29/1/202407:00GLOBE4DMT to Host Corporate Webcast to Discuss Interim Data from..
25/1/202415:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202415:50EDGAR2Form 144 - Report of proposed sale of securities
23/1/202407:00GLOBE4DMT Receives Rare Pediatric Disease Designation from FDA..
08/1/202415:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:49EDGAR2Form 144 - Report of proposed sale of securities
04/1/202416:48EDGAR2Form 144 - Report of proposed sale of securities
04/1/202407:30EDGAR2Form 8-K - Current report
04/1/202407:00GLOBE4DMT Highlights Recent Clinical Pipeline Progress, Near-Term..
03/1/202407:01GLOBE4DMT and Arbor Biotechnologies Establish Partnership to..
21/12/202311:31DJN4D Molecular Shares Rise on FDA Designation for Wet AMD Drug
21/12/202307:00GLOBE4DMT Receives FDA Regenerative Medicine Advanced Therapy..
18/12/202316:16EDGAR2Form 144 - Report of proposed sale of securities
15/12/202316:24EDGAR2Form 144 - Report of proposed sale of securities
13/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202307:00GLOBE4DMT to Present Interim 24 Week Data from Randomized Phase 2..
22/11/202315:20EDGAR2Form 8-K - Current report
15/11/202307:00GLOBE4DMT to Participate in Upcoming Investor Conferences
09/11/202315:23EDGAR2Form 8-K - Current report
09/11/202315:19GLOBE4DMT Reports Third Quarter 2023 Financial Results and..
01/11/202315:00GLOBE4DMT Presents Positive Interim Data from Phase 1/2 AEROW..

Su Consulta Reciente

NASDAQ
FDMT
4D Molecular Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados